Lumos Diagnostics announced its Chief Executive Officer, Doug Ward, has been appointed to Lumos Diagnostics' Board of Directors as Managing Director. Doug Ward was appointed and commenced as CEO of Lumos in June 2022. Doug has over 30 years experience as an executive in the diagnotics and healthcare industries.

He joined from his previous role at the leading US women's healthcare company, Hologic. Prior to this, Doug was CEO of PDGX, a genomics in vitro diagnostics company that was acquired by LabCorp in 2022 for USD 575 million. Since his appointment, Doug has played a key role in the restructuring and refocusing of Lumos, as well as managing FebriDx through the recent FDA clearance following its rejection last year.